Boston Scientific Corporation (BSX) Sentiment Analysis

Boston Scientific Corporation (BSX) has an ST Score of 52.6 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate BSX a Buy, with a price target of $61.48 (+34.9% vs the current price). Our ST Score grades it B- (52.6/100). The ST Score is a data-driven signal, not a recommendation.

Valuation D, Profitability A, Financial Strength C-, Momentum C, Growth B-, Forecast C+, Sentiment B-.

Boston Scientific Corporation (BSX) earns a valuation grade of D, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Boston Scientific Corporation (BSX) earns a growth grade of B-, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Boston Scientific Corporation (BSX) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Boston Scientific Corporation (BSX) earns a financial strength grade of C-, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Boston Scientific Corporation (BSX) is $61.48 from 44 analysts, which is +34.9% versus the recent price of $45.58.

Boston Scientific Corporation (BSX) has a Piotroski F-Score of 8 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.